News

Kalorama: Worldwide sales of flu vaccines dropped 30% from 2010 to 2011

BY Michael Johnsen

NEW YORK — For the first time in a decade, sales of vaccines declined, Kalorama Information noted in a report released Thursday. A weak flu season last year was one factor that led to a 30% decline in the market to $19.8 billion in 2011, down from $24.1 billion in 2010. However, Kalorama projects that the world vaccines market will rebound — increasing at a compound annual rate of 8.9% during 2011-2016.

"What goes up must come down and so it is with vaccine sales," stated Bruce Carlson, publisher of Kalorama Information. "We should be clear that our estimate reflects overall vaccine sales, and these results mostly have to do with influenza and a few other categories and do not change the overall trend that pharmaceutical companies are heavily interested in vaccines as part of their growth strategies."

The report said that while sales of adult influenza vaccines had been strong in 2009 and 2010 due to government stockpiling — and in some cases, over-purchasing — of new avian and swine flu vaccines, sales have since returned to earlier, pre-pandemic levels. All of the major flu vaccine manufacturers reported significant declines from 2010.

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

FDA approves new cancer drug

BY Alaric DeArment

SAN FRANCISCO — The Food and Drug Administration has approved a new drug for colorectal cancer developed by Bayer HealthCare.

Bayer and Onyx Pharmaceuticals announced the approval of Stivarga for colorectal cancer that has spread to other parts of the body, also known as metastatic CRC, specifically for those patients who have received treatment with currently available therapies.

Bayer developed the drug and will pay royalties to Onyx on future global net sales of the drug for cancer. The two companies will promote the drug together in the United States.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

New e-commerce site dedicated to eco-friendly products

BY Allison Cerra

JERSEY CITY, N.J. — The company behind Soap.com has debuted an online shopping destination for natural, organic and sustainable products.

Quidsi, a wholly owned subsidiary of Amazon, announced the premiere of Vine.com, a site that sells everything from paraben-free skin care and gluten-free snacks to reclaimed wood furnishings and solar-powered electronics. How it works: Before carrying a product, Vine.com reviews product descriptions (including descriptions of ingredients and materials) that are provided by a vendor. To be available on Vine.com, a product must fall into at least one of the following categories:

  • Designed to remove toxins;

  • Energy efficient;

  • Natural;

  • Organic;

  • Powered by renewable energy;

  • Reusable;

  • Made of sustainable materials; and/or

  • Water efficient.

Vine.com also features personal shopping tools that helps consumers easily find the types of products they are looking for. Quidsi also noted that customers receive free one- to two-day delivery on orders of $49 or more and all items are backed by Vine.com’s 365-day guarantee return policy.

"Millions of people have connected with Quidsi since we launched Diapers.com," Quidsi cofounder and CEO Marc Lore said. "In talking with them, we learned that there is a deep interest in living a green, healthy lifestyle, particularly among new parents, but that they had to work really hard to do so. People were also put off by the myth that green products are hard to find and less effective. We see an enormous opportunity with Vine.com to dispel those myths."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?